TY - JOUR
T1 - Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes
T2 - results from the TEDDY study
AU - Ancillary Studies
AU - Diet
AU - Genetics
AU - Human Subjects/Publicity/Publications
AU - Immune Markers
AU - Infectious Agents
AU - Laboratory Implementation
AU - Maternal Studies
AU - Psychosocial
AU - Quality Assurance
AU - Steering
AU - Study Coordinators
AU - Celiac Disease
AU - Clinical Implementation
AU - TEDDY study group
AU - Köhler, Meike
AU - Beyerlein, Andreas
AU - Vehik, Kendra
AU - Greven, Sonja
AU - Umlauf, Nikolaus
AU - Lernmark, Åke
AU - Hagopian, William A.
AU - Rewers, Marian
AU - She, Jin-Xiong
AU - Toppari, Jorma
AU - Akolkar, Beena
AU - Krischer, Jeffrey P.
AU - Bonifacio, Ezio
AU - Ziegler, Anette G.
AU - Bautista, Kimberly
AU - Baxter, Judith
AU - Bedoy, Ruth
AU - Felipe-Morales, Daniel
AU - Driscoll, Kimberly
AU - Frohnert, Brigitte I.
AU - Gesualdo, Patricia
AU - Hoffman, Michelle
AU - Karban, Rachel
AU - Liu, Edwin
AU - Norris, Jill
AU - Samper-Imaz, Adela
AU - Steck, Andrea
AU - Waugh, Kathleen
AU - Wright, Hali
AU - Simell, Olli G.
AU - Adamsson, Annika
AU - Ahonen, Suvi
AU - Hyöty, Heikki
AU - Ilonen, Jorma
AU - Jokipuu, Sanna
AU - Kallio, Tiina
AU - Karlsson, Leena
AU - Kähönen, Miia
AU - Knip, Mikael
AU - Kovanen, Lea
AU - Koreasalo, Mirva
AU - Kurppa, Kalle
AU - Latva-aho, Tiina
AU - Lönnrot, Maria
AU - Mäntymäki, Elina
AU - Multasuo, Katja
AU - Mykkänen, Juha
AU - Niininen, Tiina
AU - Niinistö, Sari
AU - McIndoe, Richard A
N1 - Publisher Copyright:
© 2017, Springer-Verlag Italia S.r.l.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Aims: The onset of clinical type 1 diabetes (T1D) is preceded by the occurrence of disease-specific autoantibodies. The level of autoantibody titers is known to be associated with progression time from the first emergence of autoantibodies to the onset of clinical symptoms, but detailed analyses of this complex relationship are lacking. We aimed to fill this gap by applying advanced statistical models. Methods: We investigated data of 613 children from the prospective TEDDY study who were persistent positive for IAA, GADA and/or IA2A autoantibodies. We used a novel approach of Bayesian joint modeling of longitudinal and survival data to assess the potentially time- and covariate-dependent association between the longitudinal autoantibody titers and progression time to T1D. Results: For all autoantibodies we observed a positive association between the titers and the T1D progression risk. This association was estimated as time-constant for IA2A, but decreased over time for IAA and GADA. For example the hazard ratio [95% credibility interval] for IAA (per transformed unit) was 3.38 [2.66, 4.38] at 6 months after seroconversion, and 2.02 [1.55, 2.68] at 36 months after seroconversion. Conclusions: These findings indicate that T1D progression risk stratification based on autoantibody titers should focus on time points early after seroconversion. Joint modeling techniques allow for new insights into these associations.
AB - Aims: The onset of clinical type 1 diabetes (T1D) is preceded by the occurrence of disease-specific autoantibodies. The level of autoantibody titers is known to be associated with progression time from the first emergence of autoantibodies to the onset of clinical symptoms, but detailed analyses of this complex relationship are lacking. We aimed to fill this gap by applying advanced statistical models. Methods: We investigated data of 613 children from the prospective TEDDY study who were persistent positive for IAA, GADA and/or IA2A autoantibodies. We used a novel approach of Bayesian joint modeling of longitudinal and survival data to assess the potentially time- and covariate-dependent association between the longitudinal autoantibody titers and progression time to T1D. Results: For all autoantibodies we observed a positive association between the titers and the T1D progression risk. This association was estimated as time-constant for IA2A, but decreased over time for IAA and GADA. For example the hazard ratio [95% credibility interval] for IAA (per transformed unit) was 3.38 [2.66, 4.38] at 6 months after seroconversion, and 2.02 [1.55, 2.68] at 36 months after seroconversion. Conclusions: These findings indicate that T1D progression risk stratification based on autoantibody titers should focus on time points early after seroconversion. Joint modeling techniques allow for new insights into these associations.
KW - Autoantibodies
KW - Joint modeling
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85028622724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028622724&partnerID=8YFLogxK
U2 - 10.1007/s00592-017-1033-7
DO - 10.1007/s00592-017-1033-7
M3 - Article
C2 - 28856522
AN - SCOPUS:85028622724
SN - 0940-5429
VL - 54
SP - 1009
EP - 1017
JO - Acta Diabetologica
JF - Acta Diabetologica
IS - 11
ER -